Dorothy L Reynolds, MD | |
101 W Main St, Zearing, IA 50278 | |
(641) 487-7779 | |
(641) 487-7749 |
Full Name | Dorothy L Reynolds |
---|---|
Gender | Female |
Speciality | Family Medicine |
Location | 101 W Main St, Zearing, Iowa |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255304515 | NPI | - | NPPES |
3039776 | Medicaid | IA | |
37095 | Other | IA | BCBS |
4039776 | Medicaid | IA | |
2039776 | Medicaid | IA | |
37094 | Other | IA | BCBS |
0634600 | Medicaid | IA | |
37096 | Other | IA | BCBS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 25792 (Iowa) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dorothy L Reynolds, MD 101 W Main St, Zearing, IA 50278 Ph: (641) 487-7779 | Dorothy L Reynolds, MD 101 W Main St, Zearing, IA 50278 Ph: (641) 487-7779 |
News Archive
One of the doctors who will NOT be standing behind the President today is one of his most vocal opponents. But he would have been there if the White House had its way.
A national sickle cell disease study involving Medical University of South Carolina researchers found that for some children with sickle cell disease, the drug hydroxyurea is as effective as blood transfusions to reduce blood flow speeds in the brain. Increased blood flows are a major risk factor for stroke in these children.
Politically, the biggest challenges facing the ACA are behind us. By my count, the law has already survived three near-death experiences: the Democrats' loss of a filibuster-proof Senate majority with the election of Scott Brown in Jan. 2010, the Supreme Court's June 2012 decision upholding (with one exception) the law's constitutionality, and President Obama's re-election last Nov. Much of what we see going on in Washington now is the death throes of the opposition, especially now that Americans are beginning to sign up for coverage (John McDonough, 10/9).
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
PumpStart, a community service-learning program created by students at Boston University School of Medicine, that teaches hands-only CPR to the general public, is effective for both teaching high school students a life-saving skill and providing medical students with an opportunity to engage in public health and medical education.
› Verified 7 days ago